EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance

Risheng Huang iD, Danni Wu, Kangliang Zhang, Guanqiong Hu, Yu Liu, Yi Jiang, Chichao Wang, Yuanliang Zheng

Cancer Science · 2024

DOI: 10.1111/cas.16052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Risheng Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China. Hauptthemen laut MEDLINE: Prolyl Hydroxylases, Lung Neoplasms, Protein Disulfide-Isomerases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Collaborative education project of industry university cooperation of the Ministry of Education of China, Key Laboratory of Precision Medicine of Wenzhou of China, Natural Science Foundation of Zhejiang Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss of AT‐interacting domain‐rich protein 1A ( ARID1A ) frequently occurs in human malignancies including lung cancer. The biological consequence of ARID1A mutation in lung cancer is not fully understood. This study was designed to determine the effect of ARID1A ‐depleted lung cancer cells on fibroblast activation. Conditioned media was collected from ARID1A ‐depleted lung cancer cells and employed to treat lung fibroblasts. The proliferation and migration of lung fibroblasts were investigated. The secretory genes were profiled in lung cancer cells upon ARID1A knockdown. Antibody‐based neutralization was utilized to confirm their role in mediating the cross‐talk between lung cancer cells and fibroblasts. NOD‐SCID‐IL2RgammaC‐null (NSG) mice received tumor tissues from patients with ARID1A‐mutated lung cancer to establish patient‐derived xenograft (PDX) models. Notably, ARID1A ‐depleted lung cancer cells promoted the proliferation and migration of lung fibroblasts. Mechanistically, ARID1A depletion augmented the expression and secretion of prolyl 4‐hydroxylase beta (P4HB) in lung cancer cells, which induced the activation of lung fibroblasts through the β‐catenin signaling pathway. P4HB‐activated lung fibroblasts promoted the proliferation, invasion, and chemoresistance in lung cancer cells. Neutralizing P4HB hampered the tumor growth and increased cisplatin cytotoxic efficacy in two PDX models. Serum P4HB levels were higher in ARID1A ‐mutated lung cancer patients than in healthy controls. Moreover, increased serum levels of P4HB were significantly associated with lung cancer metastasis. Together, our work indicates a pivotal role for P4HB in orchestrating the cross‐talk between ARID1A ‐mutated cancer cells and cancer‐associated fibroblasts during lung cancer progression. P4HB may represent a promising target for improving lung cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prolyl HydroxylasesLung NeoplasmsProtein Disulfide-IsomerasesHumansAnimalsMiceDrug Resistance, NeoplasmCell Line, TumorCell ProliferationMice, Inbred NODMice, SCIDCell Transformation, NeoplasticLungFibroblastsDNA-Binding ProteinsTranscription FactorsProcollagen-Proline Dioxygenase

Stichwörter der Autor:innen

ARID1AP4HBcancer-associated fibroblastmicroenvironment

Substanzen

Prolyl HydroxylasesARID1A protein, humanDNA-Binding ProteinsTranscription FactorsP4HB protein, humanProcollagen-Proline DioxygenaseProtein Disulfide-Isomerases

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.
  • Department of Central Lab, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.
  • Department of Nursing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Pathology, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.

ORCID-Profile: Risheng Huang

Förderung

  • Collaborative education project of industry university cooperation of the Ministry of Education of China
  • Key Laboratory of Precision Medicine of Wenzhou of China
  • Natural Science Foundation of Zhejiang Province, China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Huang, R., Wu, D., Zhang, K., Hu, G., Liu, Y., Jiang, Y., Wang, C., & Zheng, Y. (2024). ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance. Cancer Science. https://doi.org/10.1111/cas.16052

Vancouver

Huang R, Wu D, Zhang K, Hu G, Liu Y, Jiang Y, et al. ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance. Cancer Science. 2024. doi:10.1111/cas.16052

BibTeX
@article{Huang2024,
  author = {Huang, Risheng and Wu, Danni and Zhang, Kangliang and Hu, Guanqiong and Liu, Yu and Jiang, Yi and Wang, Chichao and Zheng, Yuanliang},
  title = {ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16052}
}
Kostenlos starten →